Published in Drugs on June 01, 1990
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother (1998) 2.59
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev (2006) 2.39
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19
Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother (2005) 1.97
Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol (2003) 1.70
Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother (1993) 1.54
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother (2007) 1.48
Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clin Pharmacol Ther (2011) 1.47
Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother (2004) 1.46
Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother (1991) 1.37
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother (2005) 1.30
Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother (1994) 1.23
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother (1998) 1.23
Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother (1998) 1.19
Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. J Clin Microbiol (1999) 1.17
Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1998) 1.15
Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol (1991) 1.15
Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother (1999) 1.14
Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol (2009) 1.11
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother (1999) 1.06
Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother (1995) 1.04
Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother (1995) 1.02
Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis (2004) 1.02
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob Agents Chemother (2008) 1.01
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother (1999) 1.01
Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother (2005) 0.98
Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob Agents Chemother (1995) 0.96
Safety of fluconazole in paediatrics: a systematic review. Eur J Clin Pharmacol (2013) 0.94
Antifungal agents for common paediatric infections. Can J Infect Dis Med Microbiol (2008) 0.93
Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles. Antimicrob Agents Chemother (2001) 0.90
Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. Br J Clin Pharmacol (2003) 0.88
Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 0.85
Sequential antibiotic therapy: Effective cost management and patient care. Can J Infect Dis (1995) 0.83
The Rho1 GTPase-activating protein CgBem2 is required for survival of azole stress in Candida glabrata. J Biol Chem (2011) 0.82
Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother (1995) 0.82
Fungal skin infections. Arch Dis Child (1992) 0.81
Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. Br J Clin Pharmacol (2001) 0.80
Antifungal agents for common paediatric infections. Paediatr Child Health (2000) 0.79
In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey. Jundishapur J Microbiol (2015) 0.79
Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis (2015) 0.77
In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran. Curr Med Mycol (2016) 0.77
Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol (2007) 0.75
Effects of cytochrome p450 inhibitors on itraconazole and fluconazole induced cytotoxicity in hepatocytes. J Toxicol (2009) 0.75
Antifungal agents for common paediatric infections. Paediatr Child Health (2007) 0.75
Antifungal therapy: from amphotericin B to present. Trans Am Clin Climatol Assoc (1993) 0.75
New treatments for vulvovaginal candidiasis. Infect Dis Obstet Gynecol (1996) 0.75
Successful treatment of brainstem blastomycosis with fluconazole. Clin Med Res (2011) 0.75
Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments. Clin Exp Immunol (1994) 0.75
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. Antimicrob Agents Chemother (2017) 0.75
Fluconazole Pharmacokinetics in the Galleria mellonella Larvae and performance evaluation of a Bioassay compared to LC-MS/MS for haemolymph specimens. Antimicrob Agents Chemother (2017) 0.75
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs (1987) 2.54
Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs (1989) 2.41
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs (1991) 1.96
Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs (1990) 1.61
Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1987) 1.43
Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs (1989) 1.35
Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs (1992) 1.28
Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs (1991) 1.18
Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs (1991) 1.17
Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs (1985) 1.13
Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs (1989) 1.08
Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs (1992) 1.08
Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs (1989) 1.08
Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. Drugs (1987) 1.01
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs (1986) 1.00
Paracetamol and phenacetin. Drugs (1986) 0.99
Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs (1989) 0.98
Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs (1984) 0.95
Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases. Drugs (1991) 0.91
Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease. Drugs (1987) 0.86
Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs (1988) 0.84
Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs (1987) 0.83
Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs (1990) 0.81
Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs (1989) 0.80
Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1985) 0.80
Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs (1990) 0.79
Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs (1986) 0.79
Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs (1992) 0.77
Aspirin and related derivatives of salicylic acid. Drugs (1986) 0.77
Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs (1990) 0.76
Sulconazole. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs (1988) 0.75
Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract (2010) 0.75
Doxacurium. A review of its pharmacology and clinical potential in anaesthesia. Drugs (1991) 0.75
Proquazone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states. Drugs (1987) 0.75
Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1987) 0.75
Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs (1990) 0.75
Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction. Drugs (1990) 0.75
Proceedings: Some pharmacological studies on uraemia. J Pharm Pharmacol (1975) 0.75